MPR YIR COPID 2020

Fixed-Dose, Triple-Combination Therapy Effective in COPD Trial

AstraZeneca announced positive results from the phase 3 ETHOS trial of PT010 for patients with moderate to very severe chronic obstructive pulmonary disease (COPD). PT010 is a single inhaler, fixed-dose triple-combination therapy of budesonide, an inhaled corticosteroid (ICS) with glycopyrronium, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long-acting beta2-agonist (LABA). The treatment is…